(1 - 13 von 13
)
Latest news about Jerry Lanchbury - Stock Market | bentoncourier ...business.bentoncourier.com › news
business.bentoncourier.com
Data & News supplied by www.cloudquote.io. Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the ...
AZ deepens ties with Myriad on Lynparza companion test - PharmaTimes
www.pharmatimes.com
AstraZeneca has expanded its agreement with US group Myriad Genetics to identify women with advanced ovarian cancer most likely to benefit from its medicines....
Combined score enhances understanding of breast cancer risk
www.healio.com
SAN ANTONIO — A risk score based on clinical, familial and genetic factors improved 5-year and lifetime predictions of breast cancer risk among women who...
FDA Approves Myriad's myChoice® CDx Test to Help Identify ...apnews.com › ...
apnews.com
... GlaxoSmithKline on its FDA approval of Zejula for women with ovarian cancer,” said Jerry Lanchbury, Ph.D., chief scientific officer of Myriad.
Helicopter service in Welshpool branches out with Majorca service |...
www.countytimes.co.uk
A HELICOPTER company which has flown top footballers and Formula One drivers to top destinations, is set to expand from its Welshpool base across to…
Myriad Data Supports Polygenic Score Value Even in Canonical Mutation...
www.precisiononcologynews.com
The company plans to make its PRS offering, currently used only in those who test negative for gene mutations, an option for all customers of European ancestry.
Myriad Genetics Expands Strategic Research Collaboration ...www.technologynetworks.com › m...
www.technologynetworks.com
... companion diagnostics to advance care for patients with lung cancer," said Jerry Lanchbury, chief scientific officer, Myriad Genetics. "If we are ...
Myriad Genetics Announces Expanded Research Collaboration
www.globenewswire.com
First Phase III PARP Inhibitor Clinical Trial to Use myChoice® HRD Plus as a Potential Companion Diagnostic...
Myriad Validates Polygenic Score to Predict Breast Cancer Riskinvestingnews.com › company-news
investingnews.com
... genetic information about their lifetime risk of developing breast cancer,” said Jerry Lanchbury, Ph.D., chief scientific officer, Myriad Genetics.
Myriad's PROLARIS(R) Test Shown to Significantly Predict ...www.nbcnews.com › wbna
www.nbcnews.com
"These findings are of great potential clinical significance," stated Jerry Lanchbury Ph.D., Chief Scientific Officer of Myriad Genetics, Inc. "We ...
Myriad’s Polygenic Risk Score Personalizes Risk of Breast
www.globenewswire.com
New Clinical Validation Study Presented at San Antonio Breast Cancer Symposium...
Ruby Haworth Winter | Powell Tribune
powelltribune.com
She was born March 21, 1921, in Alamosa, Colo., to Jerry and Anna Gullion. Her family came from Nebraska in and homesteaded at Whistle Creek. In 1938, she...
sortiert nach Relevanz / Datum